Matthew Vickers
Psychiatric/Mental Health · Plano, TXNPI 1013494566
Payments from drug & device makers
Across 484 payments — averaging $12.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$700
- Sunovion Pharmaceuticals Inc.$562
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$466
- Ironshore Pharmaceuticals Inc.$400
- Johnson & Johnson$391
- plus $2K from 21 others
What the payments were for
- Food & beverage$6,22099%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 125 | $1,333 |
| Otsuka America Pharmaceutical, Inc. | 57 | $700 |
| Sunovion Pharmaceuticals Inc. | 42 | $562 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $466 |
| Ironshore Pharmaceuticals Inc. | 32 | $400 |
| Johnson & Johnson | 35 | $391 |
| Lundbeck LLC | 27 | $360 |
| Corium, LLC | 21 | $266 |
| Supernus Pharmaceuticals, Inc. | 14 | $243 |
| Tris Pharma Inc | 13 | $209 |
| Avanir Pharmaceuticals, Inc. | 14 | $194 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $172 |
| Neurocrine Biosciences, Inc. | 8 | $157 |
| Bausch Health US, LLC | 8 | $124 |
| Axsome Therapeutics, Inc. | 4 | $112 |
| Alkermes, Inc. | 6 | $111 |
| Teva Pharmaceuticals USA, Inc. | 4 | $70 |
| Neos Therapeutics, LP | 4 | $68 |
| Jazz Pharmaceuticals Inc. | 4 | $65 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61 |
| Merck | 3 | $43 |
| Adlon Therapeutics L.p. | 3 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Almatica Pharma LLC | 2 | $29 |
| Indivior Inc. | 2 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
How this compares
$6,267 in reported general payments places this provider in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Perphenazine | 12 | $596 |
| Duloxetine Hcl | 14 | $543 |
| Olanzapine | 12 | $409 |
| Clonazepam | 14 | $261 |
| Guanfacine Hcl ErGuanfacine Hcl | 12 | $254 |
| Oxcarbazepine | 12 | $243 |
| Doxepin Hcl | 13 | $227 |
| Zolpidem Tartrate | 25 | $215 |
| Trazodone Hcl | 24 | $189 |
| Benztropine Mesylate | 11 | $184 |
| Fluoxetine Hcl | 22 | $168 |
| Sertraline Hcl | 17 | $155 |
| Lorazepam | 17 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $29 | $15517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Plano
- Christina ZazayPlano$16K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.